Since Zemdri was approved and denied for complicated Urinary Tract Infections and Blood Stream Infections, respectively, shares of Achaogen have slipped considerably.
Even though Zemdri is only be approved for cUT, experienced physicians can still prescribe it off-label. That aside, Achaogen recently earned the CARB-X award, thereby giving credence to its meds.
I think this is a case of market overreaction and market manipulation.
I see Achaogen as an investment opportunity that suffered a temporary dramatic depreciation. It is now a significant bargain for willing opportunistic investors.